Moderna surprises the Street by predicting a bigger-than-expected sales drop
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$1 per week for 24 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 13/01/2025 (290 days ago), so information in it may no longer be current.
Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year.
Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet.
The company also said it was speeding up and expanding a cost-cutting plan. It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026.
Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or respiratory syncytial virus. The company said that generated minimal sales in the year.
Moderna made its announcement Monday ahead of a presentation at the annual J.P. Morgan Healthcare Conference in San Fransisco. The company will detail its fourth-quarter results on Feb. 14.
Moderna is a couple years removed from pulling in more than $19 billion in sales annually after initial vaccination rounds during the pandemic.
Shares of Cambridge, Massachusetts-based Moderna Inc. fell 19%, or $8.18, to $34.07 in morning trading.
Related Articles
Province oddly silent on disturbingly low COVID vax rates
Advertisement Advertise With Us